The biggest drawback to drug-eluting stents has been the requirement for prolonged dual antiplatelet (DAPT) therapy following stent implantation to prevent stent thrombosis and other potential ...
Abbott (NYSE:ABT) won approval from the Japanese Ministry of Health, Labor and Welfare for its Xience V drug-eluting stent. Abbot said it plans to bring the device to market as soon as it receives ...
NATIONAL HARBOR, MD—At 3 years, the bioresorbable-polymer Orsiro stent maintains an advantage over the durable-polymer Xience, according to new data from the BIOFLOW V study. Compared with PCI ...
The Absorb BVS performs comparably to the Xience V everolimus-eluting stent through 1 year in patients with coronary artery disease, according to results of the ABSORB China trial presented yesterday ...
Xience Xpedition 48 is the latest addition to Abbott Labs’ Xience drug-eluting stent franchise. The product is designed to enable treatment for very long blockages in the vessels that supply blood to ...
September 24, 2010 (Washington, DC) — Another day at TCT 2010 brings yet more data supporting the everolimus-eluting Xience V stent (Abbott), this time in head-to-head comparisons with the ...
The US Food and Drug Administration (FDA) has approved 1-month — as short as 28 days — dual antiplatelet therapy (DAPT) labeling for Xience stents in patients at high risk for bleeding, Abbott ...
- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ...
NEW ORLEANS, March 24 (Reuters) - The drug-coated stent made by Abbott Laboratories Inc. demonstrated superiority over Boston Scientific Corp's top-selling Taxus stent, according to results of a ...
WASHINGTON, Oct. 13 Data from an independentmeta-analysis of Abbott's SPIRIT II and SPIRIT III randomized clinical trialsdemonstrated that the XIENCE V(TM) Everolimus Eluting Coronary Stent ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The US FDA has approved Xience Prime, a next generation everolimus eluting coronary stent system for patients with coronary artery disease. According to Abbot Laboratories, this new stent offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results